Search
Amylyx Pharmaceuticals Inc
AMLXAdd to Watchlist
32.410USD
-1.530-4.51%
Close 09-18 16:00（ET）
3.61BMarket Cap
LossP/E TTM
After-hours 17:43 (ET)32.540USD+0.150+0.46%
After-hours 17:43 (ET)Amylyx Pharmaceuticals Inc (AMLX) Stock Price Target & Forecast
Analyst Rating
Based on 12 analysts giving stock ratings to Amylyx Pharmaceuticals Inc in the past month.
Strong Buy
7 Strong Buy
4 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
42.364USD+27.79%
AMLX Analyst Recommendation Trends
In the current month, AMLX has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. AMLX average Analyst price target in the last month is 42.364.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
7
7
6
6
6
6
5
5
4
4
5
5
5
5
5
5
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
12
12
12
12
10
10
AMLX Analyst Rating for Peer Comparison
Updated: Sep 18, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, AMLX EPS is projected to reach -0.389 in FY2026Q3, following reported EPS of -0.391 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.36
-0.33
-0.36
-0.39
-0.38
Actual
-0.30
-0.37
-0.39
--
--
Surprise
+16.40%
-13.07%
-8.21%
--
--
FAQs
What is Amylyx Pharmaceuticals Inc's price target?
Analysts forecast that Amylyx Pharmaceuticals Inc's price target is USD 42.36, with the highest forecast at USD 57.00 and the lowest forecast at USD 20.00.
How have Amylyx Pharmaceuticals IncAMLX's recent earnings per share performed?
The market expectation was USD -0.39, while Amylyx Pharmaceuticals IncAMLX's earnings per share (EPS) for the previous quarter was USD -0.37. EPS for the next quarter is expected at USD -0.39.
What is the analyst rating for Amylyx Pharmaceuticals Inc?
Based on the ratings of Amylyx Pharmaceuticals Inc's stock from 12 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.